Alnylam plunges as earnings deliver 'one-two punch'
Alnylam plunges as earnings deliver 'one-two punch'
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ: ALNY) is the leading RNAi therapeutics company, with six approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Qfitlia, and the Leqvio collaboration with Novartis) and a deep pipeline in cardiometabolic, hepatic infectious disease, and CNS indications. Alnylam's approved medicines target transthyretin amyloidosis (Onpattro, Amvuttra), acute hepatic porphyria (Givlaari), primary hyperoxaluria type 1 (Oxlumo), and hemophilia A and B (Qfitlia). Leqvio (inclisiran), licensed to and commercialized by Novartis, targets LDL cholesterol.
Company Info
Sector:RNA Therapeutics
Headquarters:Cambridge, Massachusetts, USA
Founded:2002
Website:www.alnylam.com/
Recent News
Alnylam's slump deepens; Q2 earnings roundup; and more
Alnylam's stock slide deepened as the company reported second-quarter earnings, part of a broader biotech Q2 earnings roundup.
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock. Reported by Endpoints News on 2026-07-30.
Alnylam scolded over promotional activity after Pfizer complaint
Alnylam Pharmaceuticals faces regulatory scrutiny over promotional practices following a complaint by Pfizer.
Alnylam scolded over promotional activity after Pfizer complaint
Alnylam drew regulatory scrutiny over its promotional activity after a complaint from Pfizer, highlighting ongoing tension between innovators and generic / biosimilar competitors.
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Careers & Job Openings